ReP USP - Resultado da busca

Artigo de periodico
Impact of achieving optimal treatment targets and minimal disease activity on Health-Related Quality of Life and Satisfaction in patients with Atopic Dermatitis (2025)
Silverberg, Jonathan I.; Gooderham, Melinda; Wollenberg, Andreas; Pink, Andrew E.; Dasilva, Diego Ruiz; Kwatra, Shawn G.; Binamer, Yousef; Katoh, Norito; Aoki, Valeria ; Moreira, Alvaro
Source: Dermatology and Therapy. Unidade: FM
Subjects: DERMATITE DE CONTATO, RESULTADO DE TRATAMENTO, QUALIDADE DE VIDA, INFLAMAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVERBERG, Jonathan I. et al. Impact of achieving optimal treatment targets and minimal disease activity on Health-Related Quality of Life and Satisfaction in patients with Atopic Dermatitis. Dermatology and Therapy, v. 15, n. 8, p. 2255-2273, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/88314. Acesso em: 01 maio 2026.
APA
Silverberg, J. I., Gooderham, M., Wollenberg, A., Pink, A. E., Dasilva, D. R., Kwatra, S. G., et al. (2025). Impact of achieving optimal treatment targets and minimal disease activity on Health-Related Quality of Life and Satisfaction in patients with Atopic Dermatitis. Dermatology and Therapy, 15( 8), 2255-2273. doi:10.1007/s13555-025-01469-0
NLM
Silverberg JI, Gooderham M, Wollenberg A, Pink AE, Dasilva DR, Kwatra SG, Binamer Y, Katoh N, Aoki V, Moreira A. Impact of achieving optimal treatment targets and minimal disease activity on Health-Related Quality of Life and Satisfaction in patients with Atopic Dermatitis [Internet]. Dermatology and Therapy. 2025 ; 15( 8): 2255-2273.[citado 2026 maio 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/88314
Vancouver
Silverberg JI, Gooderham M, Wollenberg A, Pink AE, Dasilva DR, Kwatra SG, Binamer Y, Katoh N, Aoki V, Moreira A. Impact of achieving optimal treatment targets and minimal disease activity on Health-Related Quality of Life and Satisfaction in patients with Atopic Dermatitis [Internet]. Dermatology and Therapy. 2025 ; 15( 8): 2255-2273.[citado 2026 maio 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/88314
Artigo de periodico
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future (2022)
Ferrari, Filipe; Scheffel, Rafael S.; Martins, Vitor M.; Santos Filho, Raul Dias dos ; Stein, Ricardo
Source: American journal of cardiovascular drugs. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERRARI, Filipe et al. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future. American journal of cardiovascular drugs, v. 22, n. 4, p. 363-383, 2022Tradução . . Disponível em: https://doi.org/10.1007/s40256-021-00515-4. Acesso em: 01 maio 2026.
APA
Ferrari, F., Scheffel, R. S., Martins, V. M., Santos Filho, R. D. dos, & Stein, R. (2022). Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future. American journal of cardiovascular drugs, 22( 4), 363-383. doi:10.1007/s40256-021-00515-4
NLM
Ferrari F, Scheffel RS, Martins VM, Santos Filho RD dos, Stein R. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future [Internet]. American journal of cardiovascular drugs. 2022 ; 22( 4): 363-383.[citado 2026 maio 01 ] Available from: https://doi.org/10.1007/s40256-021-00515-4
Vancouver
Ferrari F, Scheffel RS, Martins VM, Santos Filho RD dos, Stein R. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future [Internet]. American journal of cardiovascular drugs. 2022 ; 22( 4): 363-383.[citado 2026 maio 01 ] Available from: https://doi.org/10.1007/s40256-021-00515-4
Artigo de periodico
Managing antiphospholipid syndrome in children and adolescents: current and future prospects (2022)
Islabao, Aline Garcia; Trindade, Vitor Cavalcanti; Mota, Licia Maria Henrique da; Andrade, Danieli Castro Oliveira de ; Silva, Clovis Artur Almeida da
Source: Pediatric drugs. Unidade: FM
Subjects: CRIANÇAS, ADOLESCENTES, TROMBOSE, SINAIS E SINTOMAS, FOSFOLIPÍDEOS, COMPLICAÇÕES NA GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ISLABAO, Aline Garcia et al. Managing antiphospholipid syndrome in children and adolescents: current and future prospects. Pediatric drugs, v. 24, n. 1, p. 13-27, 2022Tradução . . Disponível em: https://doi.org/10.1007/s40272-021-00484-w. Acesso em: 01 maio 2026.
APA
Islabao, A. G., Trindade, V. C., Mota, L. M. H. da, Andrade, D. C. O. de, & Silva, C. A. A. da. (2022). Managing antiphospholipid syndrome in children and adolescents: current and future prospects. Pediatric drugs, 24( 1), 13-27. doi:10.1007/s40272-021-00484-w
NLM
Islabao AG, Trindade VC, Mota LMH da, Andrade DCO de, Silva CAA da. Managing antiphospholipid syndrome in children and adolescents: current and future prospects [Internet]. Pediatric drugs. 2022 ; 24( 1): 13-27.[citado 2026 maio 01 ] Available from: https://doi.org/10.1007/s40272-021-00484-w
Vancouver
Islabao AG, Trindade VC, Mota LMH da, Andrade DCO de, Silva CAA da. Managing antiphospholipid syndrome in children and adolescents: current and future prospects [Internet]. Pediatric drugs. 2022 ; 24( 1): 13-27.[citado 2026 maio 01 ] Available from: https://doi.org/10.1007/s40272-021-00484-w
Artigo de periodico
The Bone Biomarker Response to an Acute Bout of Exercise: A Systematic Review with Meta-Analysis (2022)
Dolan, Eimear Bernadette ; Dumas, Alina ; Keane, Karen M. ; Bestetti, Giulia; Freitas, Luisa Helena Mavalli; Gualano, Bruno ; Kohrt, Wendy M.; Kelley, George A. ; Pereira, Rosa Maria Rodrigues ; Sale, Craig
Source: Sports medicine. Unidade: FM
Subjects: BIOMARCADORES, REVISÃO SISTEMÁTICA, EXERCÍCIOS DE RESISTÊNCIA MUSCULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOLAN, Eimear Bernadette et al. The Bone Biomarker Response to an Acute Bout of Exercise: A Systematic Review with Meta-Analysis. Sports medicine, v. 52, n. 12, p. 2889-2908, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50391. Acesso em: 01 maio 2026.
APA
Dolan, E. B., Dumas, A., Keane, K. M., Bestetti, G., Freitas, L. H. M., Gualano, B., et al. (2022). The Bone Biomarker Response to an Acute Bout of Exercise: A Systematic Review with Meta-Analysis. Sports medicine, 52( 12), 2889-2908. doi:10.1007/s40279-022-01718-8
NLM
Dolan EB, Dumas A, Keane KM, Bestetti G, Freitas LHM, Gualano B, Kohrt WM, Kelley GA, Pereira RMR, Sale C. The Bone Biomarker Response to an Acute Bout of Exercise: A Systematic Review with Meta-Analysis [Internet]. Sports medicine. 2022 ; 52( 12): 2889-2908.[citado 2026 maio 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50391
Vancouver
Dolan EB, Dumas A, Keane KM, Bestetti G, Freitas LHM, Gualano B, Kohrt WM, Kelley GA, Pereira RMR, Sale C. The Bone Biomarker Response to an Acute Bout of Exercise: A Systematic Review with Meta-Analysis [Internet]. Sports medicine. 2022 ; 52( 12): 2889-2908.[citado 2026 maio 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50391
Artigo de periodico
Is Open-Label Placebo a New Ergogenic Aid? A Commentary on Existing Studies and Guidelines for Future Research (2020)
Saito, Tiemi; Barreto, Gabriel; Saunders, Bryan; Gualano, Bruno
Source: Sports medicine. Unidade: FM
Subjects: CAFEÍNA, PLACEBOS, EXERCÍCIO FÍSICO, PESQUISA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SAITO, Tiemi et al. Is Open-Label Placebo a New Ergogenic Aid? A Commentary on Existing Studies and Guidelines for Future Research. Sports medicine, v. 50, n. 7, p. 1225-1229, 2020Tradução . . Disponível em: https://doi.org/10.1007/s40279-020-01289-6. Acesso em: 01 maio 2026.
APA
Saito, T., Barreto, G., Saunders, B., & Gualano, B. (2020). Is Open-Label Placebo a New Ergogenic Aid? A Commentary on Existing Studies and Guidelines for Future Research. Sports medicine, 50( 7), 1225-1229. doi:10.1007/s40279-020-01289-6
NLM
Saito T, Barreto G, Saunders B, Gualano B. Is Open-Label Placebo a New Ergogenic Aid? A Commentary on Existing Studies and Guidelines for Future Research [Internet]. Sports medicine. 2020 ; 50( 7): 1225-1229.[citado 2026 maio 01 ] Available from: https://doi.org/10.1007/s40279-020-01289-6
Vancouver
Saito T, Barreto G, Saunders B, Gualano B. Is Open-Label Placebo a New Ergogenic Aid? A Commentary on Existing Studies and Guidelines for Future Research [Internet]. Sports medicine. 2020 ; 50( 7): 1225-1229.[citado 2026 maio 01 ] Available from: https://doi.org/10.1007/s40279-020-01289-6
Artigo de periodico
Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial (2020)
Nicolau, José Carlos ; Bhatt, Deepak L; Hohnloser, Stefan H; Kimura, Takeshi; Lip, Gregory Y. H; Miede, Corinna; Nordaby, Matias; Oldgren, Jonas; Steg, Philippe Gabriel; Berg, Jurrien M. ten
Source: Drugs. Unidade: FM
Subjects: ANTICOAGULANTES, ESTUDOS PROSPECTIVOS, FIBRILAÇÃO ATRIAL, QUIMIOTERAPIA COMBINADA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, José Carlos et al. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial. Drugs, v. 80, n. 10, p. 995-1005, 2020Tradução . . Disponível em: https://doi.org/10.1007/s40265-020-01323-x. Acesso em: 01 maio 2026.
APA
Nicolau, J. C., Bhatt, D. L., Hohnloser, S. H., Kimura, T., Lip, G. Y. H., Miede, C., et al. (2020). Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial. Drugs, 80( 10), 995-1005. doi:10.1007/s40265-020-01323-x
NLM
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Berg JM ten. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial [Internet]. Drugs. 2020 ; 80( 10): 995-1005.[citado 2026 maio 01 ] Available from: https://doi.org/10.1007/s40265-020-01323-x
Vancouver
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Berg JM ten. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial [Internet]. Drugs. 2020 ; 80( 10): 995-1005.[citado 2026 maio 01 ] Available from: https://doi.org/10.1007/s40265-020-01323-x
Artigo de periodico
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms (2018)
Werneck, Maira Aguiar; Kortas, Guilherme Trevizan; Andrade, Arthur Guerra de; Castaldelli-maia, Joo Mauricio
Source: Cns drugs. Unidade: FM
Subjects: TRANSTORNOS RELACIONADOS AO USO DE SUBSTÂNCIAS, CANNABIS, REVISÃO SISTEMÁTICA, CANABINOIDES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WERNECK, Maira Aguiar et al. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms. Cns drugs, v. 32, n. 12, p. 1113-1129, 2018Tradução . . Disponível em: https://doi.org/10.1007/s40263-018-0577-6. Acesso em: 01 maio 2026.
APA
Werneck, M. A., Kortas, G. T., Andrade, A. G. de, & Castaldelli-maia, J. M. (2018). A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms. Cns drugs, 32( 12), 1113-1129. doi:10.1007/s40263-018-0577-6
NLM
Werneck MA, Kortas GT, Andrade AG de, Castaldelli-maia JM. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms [Internet]. Cns drugs. 2018 ; 32( 12): 1113-1129.[citado 2026 maio 01 ] Available from: https://doi.org/10.1007/s40263-018-0577-6
Vancouver
Werneck MA, Kortas GT, Andrade AG de, Castaldelli-maia JM. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms [Internet]. Cns drugs. 2018 ; 32( 12): 1113-1129.[citado 2026 maio 01 ] Available from: https://doi.org/10.1007/s40263-018-0577-6

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Source title

Funding Agencies

Non normalized affiliation